Tags

Type your tag names separated by a space and hit enter

Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic.
Gulf J Oncolog. 2020 May; 1(33):7-18.GJ

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. In December 2019, an outbreak of atypical pneumonia known as COVID-19 was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), is characterized by rapid human-to-human transmission. Acute lymphoblastic leukemia (ALL) patients are often in need for intensive chemotherapy to induce remission that will be complicated with prolonged period of cytopenias. They are often recalled to the hospital for treatment and disease surveillance. These patients may be immunocompromised due to the underlying malignancy or anti-cancer therapy. ALL patients are at higher risk of developing life-threatening infections. Several factors increase the risk of infection and the presence of multiple risk factors in the same patient is common. Cancer patients had an estimated 2-fold increased risk of contracting SARS-CoV-2 than the general population. With the World Health Organization declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such pandemic on ALL patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the optimal management of ALL patients in any infectious pandemic. In this review, we will address the potential challenges associated with managing ALL patients during the COVID-19 infection pandemic with suggestions of some practical approaches, focusing on screening asymptomatic ALL patients, diagnostic and response evaluation and choice of chemotherapy in different scenarios and setting and use of hematopoietic stem cell transplantation (HSCT).

Authors+Show Affiliations

Department of hematology, Kuwait Cancer Control Center, Shuwaikh, Kuwait.Adult Hematology/BMT, Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia.Adult Hematology and HSCT, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.Department of hematology, Kuwait Cancer Control Center, Shuwaikh, Kuwait.Adult Hematology/BMT, Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia.Adult Hematology and HSCT, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.Adult Hematology and HSCT, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.Adult Hematology and HSCT, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32476644

Citation

Alhuraiji, Ahmad, et al. "Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic." The Gulf Journal of Oncology, vol. 1, no. 33, 2020, pp. 7-18.
Alhuraiji A, Eldadah S, Alfraih F, et al. Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. Gulf J Oncolog. 2020;1(33):7-18.
Alhuraiji, A., Eldadah, S., Alfraih, F., Pandita, R., Absi, A., Hanbali, A., Aljurf, M., & El Fakih, R. (2020). Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. The Gulf Journal of Oncology, 1(33), 7-18.
Alhuraiji A, et al. Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. Gulf J Oncolog. 2020;1(33):7-18. PubMed PMID: 32476644.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic. AU - Alhuraiji,Ahmad, AU - Eldadah,Saleem, AU - Alfraih,Feras, AU - Pandita,Ramesh, AU - Absi,Ahmad, AU - Hanbali,Amr, AU - Aljurf,Mahmoud, AU - El Fakih,Riad, PY - 2020/04/30/accepted PY - 2020/6/2/entrez PY - 2020/6/2/pubmed PY - 2020/6/4/medline SP - 7 EP - 18 JF - The Gulf journal of oncology JO - Gulf J Oncolog VL - 1 IS - 33 N2 - The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. In December 2019, an outbreak of atypical pneumonia known as COVID-19 was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARSCoV-2), is characterized by rapid human-to-human transmission. Acute lymphoblastic leukemia (ALL) patients are often in need for intensive chemotherapy to induce remission that will be complicated with prolonged period of cytopenias. They are often recalled to the hospital for treatment and disease surveillance. These patients may be immunocompromised due to the underlying malignancy or anti-cancer therapy. ALL patients are at higher risk of developing life-threatening infections. Several factors increase the risk of infection and the presence of multiple risk factors in the same patient is common. Cancer patients had an estimated 2-fold increased risk of contracting SARS-CoV-2 than the general population. With the World Health Organization declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such pandemic on ALL patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the optimal management of ALL patients in any infectious pandemic. In this review, we will address the potential challenges associated with managing ALL patients during the COVID-19 infection pandemic with suggestions of some practical approaches, focusing on screening asymptomatic ALL patients, diagnostic and response evaluation and choice of chemotherapy in different scenarios and setting and use of hematopoietic stem cell transplantation (HSCT). SN - 2078-2101 UR - https://www.unboundmedicine.com/medline/citation/32476644/Optimal_Management_of_Acute_Lymphoblastic_Leukemia__ALL__in_Adult_Patients_During_the_Novel_Coronavirus_Disease_2019__COVID_19__Pandemic_ DB - PRIME DP - Unbound Medicine ER -